{
    "clinical_study": {
        "@rank": "40256", 
        "acronym": "VIDATOPIC", 
        "arm_group": [
            {
                "arm_group_label": "Vitamin D3 supplementation", 
                "arm_group_type": "Experimental", 
                "description": "Subjects in the experimental arm will receive weekly vitamin D3 doses in oral suspension during 6 weeks. Weekly dose varies according to age group: VD3 8000 IU between ages 2-5.9 years, VD3 12000 IU between ages 6-11.9 years, VD3 16000 IU between ages 12-17.9 years."
            }, 
            {
                "arm_group_label": "Placebo", 
                "arm_group_type": "Placebo Comparator", 
                "description": "Subjects in the placebo arm will receive weekly placebo oral suspension during 6 weeks."
            }
        ], 
        "brief_summary": {
            "textblock": "The purpose of this study is to determine whether oral vitamin D supplementation improves\n      the clinical severity of atopic dermatitis in children. In addition, this study plans to\n      evaluate the effects of vitamin D supplementation on several key aspects of the immune\n      system of children with atopic dermatitis."
        }, 
        "brief_title": "Impact of Vitamin D Supplementation on Severity of Pediatric Atopic Dermatitis", 
        "completion_date": {
            "#text": "March 2016", 
            "@type": "Anticipated"
        }, 
        "condition": "Atopic Dermatitis", 
        "condition_browse": {
            "mesh_term": [
                "Dermatitis", 
                "Dermatitis, Atopic"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Atopic dermatitis diagnosed according to Hanifin and Rajka criteria\n\n          -  Age 2 - 17 years\n\n          -  SCORAD 10 - 103\n\n        Exclusion Criteria:\n\n          -  Active skin infection\n\n          -  History of underlying illness causing immunosuppression within the past 2 years\n\n          -  Immunosuppressors taken within the past month\n\n          -  Parathyroid disease\n\n          -  Sarcoidosis\n\n          -  Acute or chronic renal disease\n\n          -  Hyper or hypocalcemia\n\n          -  Thyroid disease\n\n          -  Osteomalacia or Paget's disease of bone\n\n          -  Malabsorption\n\n          -  Use of VD supplements (> 400 IU daily) or fish oil supplements in the past month\n\n          -  Treatment for known VD deficiency in the last 6 months\n\n          -  Treatment with moderate or high potency topical corticosteroids, oral or topical\n             antibiotics, oral antivirals, immune enhancers, or topical calcineurin inhibitors in\n             the past 7 days\n\n          -  Phototherapy in the past month\n\n          -  Autoimmune disease or immunodeficiency\n\n          -  Planned trip to sunny climate during the 6-week study."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "17 Years", 
            "minimum_age": "2 Years"
        }, 
        "enrollment": {
            "#text": "100", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "November 11, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01996423", 
            "org_study_id": "12-185", 
            "secondary_id": "1130615"
        }, 
        "intervention": [
            {
                "arm_group_label": "Vitamin D3 supplementation", 
                "intervention_name": "Vitamin D3", 
                "intervention_type": "Dietary Supplement", 
                "other_name": "Cholecalciferol"
            }, 
            {
                "arm_group_label": "Placebo", 
                "intervention_name": "Placebo", 
                "intervention_type": "Dietary Supplement"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Cholecalciferol", 
                "Vitamin D", 
                "Ergocalciferols", 
                "Vitamins"
            ]
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "Atopic dermatitis", 
            "vitamin D"
        ], 
        "lastchanged_date": "May 1, 2014", 
        "location": {
            "facility": {
                "address": {
                    "city": "Santiago", 
                    "country": "Chile"
                }, 
                "name": "School of Medicine, Pontificia Universidad Cat\u00f3lica de Chile"
            }, 
            "investigator": [
                {
                    "last_name": "Catalina Le Roy, M.D.", 
                    "role": "Sub-Investigator"
                }, 
                {
                    "last_name": "Rodrigo Hoyos-Bachiloglu, M.D.", 
                    "role": "Sub-Investigator"
                }, 
                {
                    "last_name": "Cristi\u00e1n Navarrete, M.D.", 
                    "role": "Sub-Investigator"
                }, 
                {
                    "last_name": "Francisca Cristi, MSc", 
                    "role": "Sub-Investigator"
                }, 
                {
                    "last_name": "Carolina Iturriaga, RN", 
                    "role": "Sub-Investigator"
                }
            ], 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "Chile"
        }, 
        "number_of_arms": "2", 
        "official_title": "Impact of Vitamin D Supplementation on Clinical Severity and Immunologic Tolerance of Pediatric Atopic Dermatitis", 
        "other_outcome": {
            "description": "Adverse events of atopic dermatitis patients with VD3 and placebo", 
            "measure": "Number of participants with adverse events", 
            "safety_issue": "Yes", 
            "time_frame": "6 weeks"
        }, 
        "overall_contact": {
            "email": "arturobor@med.puc.cl", 
            "last_name": "Arturo Borzutzky, M.D.", 
            "phone": "56-2-23543753"
        }, 
        "overall_official": [
            {
                "affiliation": "School of Medicine, Pontificia Universidad Cat\u00f3lica de Chile", 
                "last_name": "Arturo Borzutzky, M.D.", 
                "role": "Principal Investigator"
            }, 
            {
                "affiliation": "Massachusetts General Hospital, Harvard University, Boston, USA", 
                "last_name": "Carlos A Camargo Jr., M.D., DrPH", 
                "role": "Study Director"
            }, 
            {
                "affiliation": "School of Medicine, Pontificia Universidad Cat\u00f3lica de Chile", 
                "last_name": "Cristian Vera, M.D.", 
                "role": "Study Director"
            }, 
            {
                "affiliation": "School of Medicine, Pontificia Universidad Cat\u00f3lica de Chile", 
                "last_name": "Lorena Cifuentes, M.D.", 
                "role": "Study Director"
            }, 
            {
                "affiliation": "School of Medicine, Pontificia Universidad Cat\u00f3lica de Chile", 
                "last_name": "Sergio Silva, M.D.", 
                "role": "Study Director"
            }
        ], 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "Chile: Comisi\u00f3n Nacional de Investigaci\u00f3n Cient\u00edfica y Tecnol\u00f3gica", 
            "has_dmc": "No"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "December 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "Change in Scoring Atopic Dermatitis (SCORAD) index after 6 weeks of vitamin D3 (VD3) supplementation or placebo in children with atopic dermatitis.", 
            "measure": "Change in SCORAD index", 
            "safety_issue": "No", 
            "time_frame": "baseline and 6 weeks"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01996423"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "Eosinophil blood counts, serum IgE, Th2 lymphocytes among stimulated PBMCs, serum CCL17, CCL22, and CCL27.", 
                "measure": "Changes in Th2 immunity", 
                "safety_issue": "No", 
                "time_frame": "baseline and 6 weeks"
            }, 
            {
                "description": "Number and phenotype of blood dendritic cells and number of regulatory T cells.", 
                "measure": "Change in dendritic cell-mediated tolerance and regulatory T cells", 
                "safety_issue": "No", 
                "time_frame": "baseline and 6 weeks"
            }, 
            {
                "description": "Serum cathelicidin levels, S. aureus skin carriage, and specific IgE to staphylococcal enterotoxins.", 
                "measure": "Effect of VD3 supplementation on immunity to Staphylococcus aureus", 
                "safety_issue": "No", 
                "time_frame": "baseline and 6 weeks"
            }, 
            {
                "description": "Effect of VDR SNPs on the VD3 response.", 
                "measure": "Vitamin D receptor single nucleotide polymorphisms", 
                "safety_issue": "No", 
                "time_frame": "baseline and 6 weeks"
            }, 
            {
                "description": "Gene expression of epidermal proteins by PCR obtained from lesional and non-lesional tape stripping samples.", 
                "measure": "Change in epidermal protein expression", 
                "safety_issue": "No", 
                "time_frame": "6 weeks"
            }
        ], 
        "source": "Pontificia Universidad Catolica de Chile", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Pontificia Universidad Catolica de Chile", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "April 2014", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "May 2014"
    }
}